M J Murphy1, J M Newby1,2, P Butow3, A Joubert2, L Kirsten3,4, J Shaw3, H L Shepherd3, G Andrews1. 1. Clinical Research Unit for Anxiety and Depression (CRUfAD), UNSW, Sydney, NSW 2010, Australia. 2. School of Psychology, UNSW, NSW 2052, Australia. 3. Psycho-oncology Co-operative Research Group (PoCoG), The University of Sydney, NSW 2006, Australia. 4. Nepean Cancer Care Centre, NSW 2747, Australia.
Abstract
PURPOSE: Evaluate the feasibility, acceptability and potential efficacy of a form of online therapy for clinical depression and/or anxiety in people living with advanced cancer. METHODS: A single-arm open trial of a six-lesson clinician-supervised, internet-delivered cognitive behavioural therapy (iCBT) transdiagnostic intervention (iCanADAPT Advanced) was undertaken. Qualitative (semi-structured telephone interview conducted at 3-months) and quantitative data (questionnaires collected at pre-, post-, and 3-month follow-up) were analysed. RESULTS: 27 participants partook (26 women, 56% breast cancer, mean age 56yo; average number of mental health diagnoses 1.8, with majority (81%) meeting criteria for generalised anxiety disorder). Feasibility - Unanticipated numbers (48%) of participants had physical health deterioration (cancer progression or death). iCBT had high adherence overall (completion rates: 37% did 6 lessons; 70% did 4 lessons) but adherence was higher for those whose cancer remained stable (completion rates: 43% did 6 lessons; 85% did 4 lessons). Acceptability - the intervention was acceptable to the majority of participants, with high treatment satisfaction. Advisory data was achieved regarding future versions. Potential efficacy - regardless of physical health status, participants who completed the iCBT showed a significant decrease over time in anxiety and depression symptoms. CONCLUSIONS: Online therapies may be useful in assisting those living with advanced cancer dealing with clinical depression and anxiety disorders. The specific modality of clinician supervised iCBT has significant potential to be a suitable modality of online therapy.
PURPOSE: Evaluate the feasibility, acceptability and potential efficacy of a form of online therapy for clinical depression and/or anxiety in people living with advanced cancer. METHODS: A single-arm open trial of a six-lesson clinician-supervised, internet-delivered cognitive behavioural therapy (iCBT) transdiagnostic intervention (iCanADAPT Advanced) was undertaken. Qualitative (semi-structured telephone interview conducted at 3-months) and quantitative data (questionnaires collected at pre-, post-, and 3-month follow-up) were analysed. RESULTS: 27 participants partook (26 women, 56% breast cancer, mean age 56yo; average number of mental health diagnoses 1.8, with majority (81%) meeting criteria for generalised anxiety disorder). Feasibility - Unanticipated numbers (48%) of participants had physical health deterioration (cancer progression or death). iCBT had high adherence overall (completion rates: 37% did 6 lessons; 70% did 4 lessons) but adherence was higher for those whose cancer remained stable (completion rates: 43% did 6 lessons; 85% did 4 lessons). Acceptability - the intervention was acceptable to the majority of participants, with high treatment satisfaction. Advisory data was achieved regarding future versions. Potential efficacy - regardless of physical health status, participants who completed the iCBT showed a significant decrease over time in anxiety and depression symptoms. CONCLUSIONS: Online therapies may be useful in assisting those living with advanced cancer dealing with clinical depression and anxiety disorders. The specific modality of clinician supervised iCBT has significant potential to be a suitable modality of online therapy.
Authors: R D Nipp; A El-Jawahri; M Ruddy; C Fuh; B Temel; S M D'Arpino; B J Cashavelly; V A Jackson; D P Ryan; E P Hochberg; J A Greer; J S Temel Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Shannon Sauer-Zavala; Cassidy A Gutner; Todd J Farchione; Hannah T Boettcher; Jacqueline R Bullis; David H Barlow Journal: Behav Ther Date: 2016-09-25
Authors: D Dirkse; H D Hadjistavropoulos; N A Alberts; E Karin; L H Schneider; N Titov; B F Dear Journal: J Cancer Surviv Date: 2019-12-18 Impact factor: 4.442
Authors: Yan Leykin; Seema M Thekdi; Dianne M Shumay; Ricardo F Muñoz; Michelle Riba; Laura B Dunn Journal: Psychooncology Date: 2011-05-24 Impact factor: 3.894
Authors: Elaine O Cheung; Michael A Cohn; Laura B Dunn; Michelle E Melisko; Stefana Morgan; Frank J Penedo; John M Salsman; Dianne M Shumay; Judith T Moskowitz Journal: Psychooncology Date: 2016-12-27 Impact factor: 3.894
Authors: Joseph A Greer; Jamie Jacobs; Nicole Pensak; James J MacDonald; Charn-Xin Fuh; Giselle K Perez; Alina Ward; Colleen Tallen; Alona Muzikansky; Lara Traeger; Frank J Penedo; Areej El-Jawahri; Steven A Safren; William F Pirl; Jennifer S Temel Journal: Oncologist Date: 2019-01-25
Authors: David Spiegel; Lisa D Butler; Janine Giese-Davis; Cheryl Koopman; Elaine Miller; Sue DiMiceli; Catherine C Classen; Patricia Fobair; Robert W Carlson; Helena C Kraemer Journal: Cancer Date: 2007-09-01 Impact factor: 6.860
Authors: R D Nipp; N K Horick; A M Deal; L J Rogak; C Fuh; J A Greer; A C Dueck; E Basch; J S Temel; A El-Jawahri Journal: Ann Oncol Date: 2020-01 Impact factor: 32.976